ITCI241220C65000
- 11.00
- 0.000.00%
Intra-Cellular Therapies Newsroom
Wolfe's Most Shorted 'Hit List' – FSLR, BE, WBA, SJM
UBS Maintains Intra-Cellular Therapies(ITCI.US) With Hold Rating, Raises Target Price to $87
Express News | Intra-Cellular Therapies Inc : UBS Raises Target Price to $87 From $79
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
US Manufacturing Index Rises To 43, Highest Since 2020
Intra-Cellular Therapies(ITCI.US) Officer Sells US$3.69 Million in Common Stock
Form 144 | Intra-Cellular Therapies(ITCI.US) Officer Proposes to Sell 3.7 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Nov 12, $Intra-Cellular Therapies(ITCI.US)$ Officer Halstead Michael intends to sell 41,583 shares of its common stock on Nov 12, with a total market value of approximately $3.
Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) P/S Is Still On The Mark Following 26% Share Price Bounce
Intra-Cellular Therapies' Treatment Reduces Schizophrenia Relapse Risk 63%
Intra-Cellular Meets Main Goal in Late Stage Trial for Its Schizophrenia Treatment
Express News | Intra-Cellular Therapies Inc - Primary Endpoint Shows Longer Time to Relapse With Lumateperone
Express News | Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating Caplyta for the Prevention of Relapse in Patients With Schizophrenia
Demystifying Intra-Cellular Therapies: Insights From 15 Analyst Reviews
Intra-Cellular Therapies Is Maintained at Overweight by JP Morgan
J.P. Morgan Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Raises Target Price to $89
Intra-Cellular Therapies Receives Buy Rating Amid Promising Sales Projections and Strategic Developments
Here's What Analysts Are Forecasting For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) After Its Third-Quarter Results
A Quick Look at Today's Ratings for Intra-Cellular Therapies(ITCI.US), With a Forecast Between $90 to $102
Intra-Cellular Therapies Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
A Quick Look at Today's Ratings for Intra-Cellular Therapies(ITCI.US), With a Forecast Between $79 to $135